FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

HRS §461-15(a)(7) makes it unlawful for any out-of-state pharmacy or entity engaging in the practice of pharmacy to distribute, ship, mail or deliver prescription drugs or devices into Hawaii without first obtaining a Board permit. The applicant must list the location and principal officers, attest that it and its personnel have not been found in violation of state or federal drug laws, verify a valid home-state license (and keep it in good standing), and employ a registered pharmacist in good standing. The Board's miscellaneous-permit instructions (PH-07(a), rev. 03/24) also ask for sealed home-state verifications of the pharmacy license and of every employed pharmacist's license; fees are $410 (even-year application) or $239 (odd-year), permits expire December 31 of odd-numbered years, and pharmacies shipping controlled substances must separately register with Hawaii's Narcotics Enforcement Division. No inspection-report, Hawaii-licensed PIC, NABP accreditation or separate sterile-compounding permit requirement was found in the statute or the instructions.

The official statute host (capitol.hawaii.gov) blocked automated fetching; statute text confirmed from FindLaw's copy (current as of 2025-01-01). The instructions form is marked revision 03/24 (month only; source date given as access date). 2025–2026 Hawaii bills on nonresident pharmacies could not be checked in this pass.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

HRS chapter 461 includes compounding in the practice of pharmacy but does not define compounding or address office use. The Board's rules (HAR chapter 16-95) regulate compounding mainly by making failure to follow USP <795> (nonsterile) and <797> (sterile) a ground for discipline (HAR §16-95-110(a)(17)); they set no office-use quantities, labeling or record rules and no express prohibition. With the state silent, the federal view applies: FDA's position is that 503A compounding requires patient-specific prescriptions. The Hawaii Board of Pharmacy (DCCA) enforces.

Silent. HAR 16-95 compilation dates from 2016 (possibly stale); no newer compounding rule was found on the Board's laws-and-rules page. Check with the Hawaii Board of Pharmacy: https://cca.hawaii.gov/pvl/boards/pharmacy/

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

HRS §461-15(a)(7) requires a Board miscellaneous permit for any out-of-state pharmacy 'or entity engaging in the practice of pharmacy' that distributes, ships, mails or delivers prescription drugs or devices into Hawaii, and §461-15(a)(6) requires a Board permit for anyone engaging in the business of preparing, manufacturing, compounding, packing or repacking any drug; the Board's miscellaneous-permit instructions list both activities. The Board's wholesale prescription drug distributor instructions say a license is needed only for wholesale distribution, storage or consignment inventory within Hawaii, and that an entity licensed in its home state with no facility, office or vendor-managed inventory in Hawaii does not need a Hawaii wholesale license. Neither the statute nor the Board's instructions mention FDA 503B outsourcing facilities by name.

Whether the §461-15(a)(6) manufacturing/compounding permit reaches a facility located outside Hawaii is not stated in the text reviewed; confirm with the Hawaii Board of Pharmacy (https://cca.hawaii.gov/pvl/boards/pharmacy/) before shipping. Controlled substances also require registration with Hawaii's Narcotics Enforcement Division. The official statute host blocked automated fetching; FindLaw copy used.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Hawaii is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

NED's practitioner instructions state that registration is required for every person who administers, prescribes or dispenses any controlled substance in Hawaii, that it is an annual registration, and that the practitioner fee is $115 (late fee $50). Applicants need an active Hawaii license and a HI-PDMP account, and apply for the federal DEA registration after receiving the Hawaii CSR; the CSR and DEA registration must show the same Hawaii address and schedules. Prescribe-only practitioners need one registration (additional prescribe-only sites are listed on it), but a separate Hawaii CSR and DEA registration are required for each location where controlled substances are kept to administer or dispense, and keeping own stock may require a pre-inspection. APRNs and PAs obtain the same registration using their own instructions; renewal requires an annual prescriber-education attestation (since 2024).

NED moved from the Department of Public Safety to the new Department of Law Enforcement on Jan. 1, 2024. HRS text itself (capitol.hawaii.gov) was blocked in this session, so the operative requirement is quoted from NED's official instructions. Per-location: yes for sites that stock/administer/dispense. Source older than 2 years - possibly stale.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Hawaii's Department of Law Enforcement (Narcotics Enforcement Division) lists Act 153 (2018, SB 2646, effective 7/1/2018) as pertaining to 'practitioner utilization requirements of the PDMP' and Act 251 (2019, HB 665) as creating exceptions to the query requirement. The PDMP TTAC mandatory-query citation list (10/29/2025) does not list Hawaii, and the TTAC Hawaii profile (printed 8/25/2025) shows only a prescriber/dispenser enrollment mandate under HRS 329-101 with no use-mandate citation. The Hawaii Revised Statutes site (capitol.hawaii.gov) blocked automated access, so the scope (e.g., whether it reaches Schedule III such as testosterone) was not verified. Contact the Narcotics Enforcement Division / Hawaii PDMP to confirm.

Hawaii is missing from the PDMP TTAC mandatory-query list, yet state sources show 2018-2019 acts on practitioner PDMP use - check with the Hawaii Department of Law Enforcement, Narcotics Enforcement Division (law.hawaii.gov) or the Hawaii PDMP (hawaii.pmpaware.net) before relying on either reading.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

HRS 328-16(b)(3) allows a practitioner to dispense prescription drugs to an ultimate user, provided the practitioner informs the patient of the right to choose a pharmacy and keeps records. The label must show the dispensing practitioner's name, office address and phone, patient name, drug name, strength and quantity, date and directions; records must include the full prescription and are open to department inspection. Controlled substances require Hawaii controlled substance registration and reporting.

Statute read on an unofficial mirror (capitol.hawaii.gov blocked automated access). A vendor summary (PharmaLink) says Hawaii physicians also need a Board of Pharmacy permit; not confirmed in the statute reviewed. Check with the Hawaii Board of Pharmacy.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Out-of-state physicians may consult with Hawaii-licensed physicians by telehealth but may not treat Hawaii patients directly without a Hawaii license. Telehealth prescribing is held to the same standards as in-person practice (HRS 453-1.3). A physician-patient relationship for prescribing opiates (or medical cannabis) requires an in-person consultation, except a three-day or smaller opiate supply when a same-group provider has seen the patient in person. No such limit applies to testosterone or other non-opioid drugs. IMLC: member, non-SPL (licenses issued only through another state of principal license).

CCHP notes HRS 453-1.3 was amended by HB 951 with a repeal-and-reenactment on December 31, 2027 (SB 1281). Hawaii Medicaid requires controlled-substance prescribers to be located in Hawaii.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Hawaii Board of Nursing (DCCA Professional & Vocational Licensing)'s website was checked on 2026-09-23 for a position statement, advisory opinion or FAQ on cosmetic injectables (neuromodulators, fillers) and none was found. RN practice therefore falls under the state's general nurse practice act, which was not reviewed for this entry.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Hawaii Board of Nursing (DCCA Professional & Vocational Licensing)'s website was checked on 2026-09-23 for guidance on IV hydration clinics (prior exams, standing orders, mobile services) and none was found.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists Hawaii as 'Permitted (Unclear)', citing Haw. Rev. Stat. §§453-2 and 448-15; MedPath Compliance (reviewed 2026-06-20) lists Hawaii as 'No (weak)'.

Both compilations flag uncertainty.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

No Hawaii statute, rule or board policy on delegation of cosmetic laser/IPL procedures or a laser-operator credential was located on 2026-09-23.

A vendor compilation reports that Hawaii electrologists may perform laser hair removal independently and PAs/nurses under physician supervision; not verified against an official source.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Hawaii was not among them, but this research did not confirm its statutes. Hawaii's CLIA state agency is Hawaii Dept. of Health CLIA Program (doh.ohcamco@doh.hawaii.gov, 808-692-7420); it can confirm whether any state license or permit applies, including to out-of-state labs.

Hawaii may run its own in-state lab licensing program; this could not be confirmed from a primary source in this pass, so check with the agency before relying on CLIA alone. ASCLS lists Hawaii among the states that license clinical laboratory personnel, which applies to labs located in the state.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Hawaii's rule. Hawaii's lab regulator (CLIA state agency) is Hawaii Dept. of Health CLIA Program (doh.ohcamco@doh.hawaii.gov, 808-692-7420). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Hawaii is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Hawaii passed legislation in 2018 prohibiting the sale of sunscreens containing oxybenzone and octinoxate, citing harm to coral reefs, and the ban has been in force since 2021. Hawaii is also listed among the states that ban the sale of cosmetics tested on animals. A statewide expansion to other UV filters (e.g., avobenzone or octocrylene) was not confirmed in this research, and county ordinances may be stricter.

The Hawaii Legislature's statute site blocked automated access, so check HRS ch. 342D and any county ordinances before shipping chemical-filter sunscreens to Hawaii. Mineral (zinc oxide or titanium dioxide) sunscreens are not affected by the oxybenzone/octinoxate ban. The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.